Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Moderna Inc Market Cap
Based on ratings from 13 stock analysts, the Moderna Inc stock price is expected to increase by 48.67% in 12 months. This is calculated by using the average 12-month stock price forecast for Moderna Inc. The lowest target is $55.00 and the highest is $310.00. Please note analyst price targets are not guaranteed and could be missed completely.
Moderna Inc has a total of 13 Wall St Analyst ratings. There are 7 buy ratings, 5 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Moderna Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| geoff meacham Bank of America Securities | Hold | $120.0 | maintained | Feb 15, 2024 |
| tyler van buren TD Cowen | Hold | $75.0 | reiterated | Feb 8, 2024 |
| william maughan Canaccord Genuity | Hold | $82.0 | maintained | Dec 14, 2023 |
| terence flynn Morgan Stanley | Hold | $92.0 | maintained | Dec 12, 2023 |
| jessica fye J.P. Morgan | Hold | $90.0 | maintained | Dec 1, 2023 |
| rajesh kumar HSBC | Hold | $69.0 | upgraded | Nov 3, 2023 |
| myles minter William Blair | Hold | $136.28 | initiatedcoverage | Jul 24, 2023 |
| geulah livshits Chardan Capital | Hold | $208.0 | reiterated | Jan 18, 2023 |
| joseph stringer Needham | Hold | None | maintained | Jan 18, 2023 |
| sachin jain Bank of America Securities | Hold | $195.0 | maintained | Jan 17, 2023 |
| simon baker cfa Redburn Partners | Hold | None | upgraded | Feb 1, 2022 |
| cory kasimov J.P. Morgan | Hold | $165.0 | maintained | Nov 4, 2021 |
| ronny gal Bernstein | Hold | None | maintained | Aug 20, 2021 |
| nick abbott Wells Fargo | Hold | $145.0 | maintained | Jun 29, 2021 |
| jim birchenough Wells Fargo | Hold | $145.0 | maintained | Feb 1, 2021 |
| alan carr Needham | Hold | None | rated | Feb 1, 2021 |
| tazeen ahmad Bank of America Securities | Hold | $150.0 | reiterated | Jan 25, 2021 |
| george farmer Scotiabank | Hold | $109.0 | downgraded | Nov 17, 2020 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2018
Staff Count
3,900
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Stephane Bancel
Market Cap
$33.69B
In 2023, MRNA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MRNA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$78.64
CSGP-USD
$83.98
EXC-USD
$36.21
CDW-USD
$247.56
$730.5
BIIB-USD
$222.48
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
